ONCY (Oncolytics Biotech) Tariff Resilience Score: 7/10 (As of Jul. 11, 2026)


ONCY Oncolytics Biotech Inc ONCY
28 GF Score
Price $0.89
! 2 Warning Signs
View Full Analysis

What is Oncolytics Biotech Tariff Resilience Score?

Oncolytics Biotech ONCY -3.55% 28 Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus rates ONCY with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,369 Biotechnology companies, Oncolytics Biotech ranks better than 90.36% on this metric.

Oncolytics Biotech has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Oncolytics Biotech has Oncolytics Biotech's operations are primarily research-focused with limited manufacturing exposure. The company has some international partnerships but is less affected by tariffs due to its niche market and potential for alternative sourcing.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Oncolytics Biotech might have Highly Resilient.

Oncolytics Biotech  (NAS:ONCY) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Oncolytics Biotech Tariff Resilience Score Related Terms

ONCY vs VRCA, ENGN, ALDX: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Oncolytics Biotech's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncolytics Biotech Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's Tariff Resilience Score falls into.


ONCY
28GF Score
Oncolytics Biotech Inc ONCY
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Oncolytics Biotech (ONCY) has a Tariff Resilience Score of 7 as of Jul. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Oncolytics Biotech ranks #132 out of 1369 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Oncolytics Biotech's Tariff Resilience Score too high?
Oncolytics Biotech's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Oncolytics Biotech's value of 7 is 75% above this industry median. Based on the distribution chart, Oncolytics Biotech ranks #132 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncolytics Biotech has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Oncolytics Biotech's Tariff Resilience Score compare to VRCA and ENGN?
According to the Biotechnology industry distribution chart, Oncolytics Biotech ranks #132 out of 1369 companies for Tariff Resilience Score. This places Oncolytics Biotech in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Oncolytics Biotech's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncolytics Biotech's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncolytics Biotech's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncolytics Biotech stock overvalued right now?
Oncolytics Biotech (ONCY) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Oncolytics Biotech's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Oncolytics Biotech (ONCY), the current Tariff Resilience Score is 7 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oncolytics Biotech Business Description

Address 4350 Executive Drive, Suite 325, San Diego, CA, USA, 92121
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer, among others.
28GF Score

Get the complete analysis for ONCY

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.89
Price